NASDAQ:ASND
Ascendis Pharma A/S Stock News
$121.12
-1.68 (-1.37%)
At Close: May 17, 2024
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
11:46am, Wednesday, 15'th May 2024
Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.
FDA extends review of Ascendis Pharma's hormone disorder therapy
02:43pm, Tuesday, 14'th May 2024
The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder, the company said on Tuesday.
- Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to August 14, 2024
COPENHAGEN, Denmark, May 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced 2-year results from a post-hoc analysis of the Company's Phase 3 PaTHway Trial demonstrating si
COPENHAGEN, Denmark, May 09, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefi
Ascendis Pharma A/S (ASND) Q1 2024 Earnings Call Transcript
12:33pm, Saturday, 04'th May 2024
Ascendis Pharma A/S (ASND) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President & Chief Executive Office
Ascendis Pharma Reports First Quarter 2024 Financial Results
04:01pm, Thursday, 02'nd May 2024
— Rollout of YORVIPATH ® initiated in Germany and Austria, with an estimated 55 doctors writing prescriptions and ~100 patients receiving commercial product as of March 31
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
04:46pm, Thursday, 25'th Apr 2024
COPENHAGEN, Denmark, April 25, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2024 financial results and provide a business update on Thursday
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
09:36am, Wednesday, 24'th Apr 2024
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
08:30am, Wednesday, 24'th Apr 2024
COPENHAGEN, Denmark, April 24, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the United Kingdom's Medicines & Healthcare products Regulatory Agency (MHRA) has grante
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
09:27am, Wednesday, 10'th Apr 2024
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Biotech With 520% Sales Growth Nears Next Buy Point
10:24am, Tuesday, 02'nd Apr 2024
This biotech growth stock is climbing its way up a base on its way to a buy point. The company's sales are expected to continue to soar.
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
08:36am, Friday, 08'th Mar 2024
We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
08:30am, Monday, 04'th Mar 2024
COPENHAGEN, Denmark, March 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global Bi
Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?
01:00pm, Thursday, 15'th Feb 2024
Does Ascendis Pharma A/S (ASND) have what it takes to be a top stock pick for momentum investors? Let's find out.